- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07777068
Ejaculation-Preserving Versus Conventional Dual Wavelength Diode Laser Vaporization of the Prostate (EP-TUVP)
Ejaculation-Preserving Versus Conventional Dual-Wavelength Diode Laser Vaporization of the Prostate: A Randomized Comparative Study With 12-Month Follow up
Surgery to relieve urinary blockage caused by an enlarged prostate works well, but most men lose antegrade ejaculation afterwards, because semen passes backwards into the bladder instead of forwards. For sexually active men this is an important concern and a common reason for delaying or refusing surgery.
This study compared two ways of performing the same operation, laser vaporization of the prostate using a dual-wavelength diode laser. In the conventional technique, prostate tissue is removed from the bladder neck all the way to the verumontanum. In the ejaculation-preserving technique, the surgeon deliberately leaves a 10 mm rim of tissue at the bladder neck untouched, and another 10 mm of tissue just before the verumontanum untouched, while removing the blocking tissue in between. Everything else about the operation, including the laser settings, was the same.
Men were assigned to one of the two techniques by a computer-generated random sequence. They were assessed before surgery and again at 7 to 14 days, 1 month, 3 months, 6 months and 12 months after surgery.
The main question was how many men still had antegrade ejaculation 3 months after surgery. The study also compared urinary symptoms, urine flow rate, residual urine volume, prostate size, erectile function, complications and patient satisfaction, to find out whether preserving ejaculation costs anything in terms of relieving the urinary blockage.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
BACKGROUND
Loss of antegrade ejaculation follows conventional transurethral resection or vaporization of the prostate in the majority of men. Two anatomical regions are considered central to this: the internal urethral sphincter at the bladder neck, which prevents retrograde passage of semen, and the paracollicular and supracollicular tissue around the verumontanum, which contributes to the emission phase. Techniques preserving one or both regions have been described across several endoscopic platforms, but evidence specific to the dual-wavelength diode laser is limited and follow-up in previous work has been short.
OBJECTIVE
To determine whether an ejaculation-preserving technique of dual-wavelength diode laser vaporization of the prostate preserves antegrade ejaculation without compromising relief of bladder outlet obstruction, and whether any benefit is durable to 12 months.
DESIGN
Prospective, randomized, single-centre comparative study conducted at the Department of Urology, Royal Hospital, Sulaymaniyah, Kurdistan Region, Iraq. Allocation followed a computer-generated random sequence, with assignments concealed in sequentially numbered opaque sealed envelopes opened after consent. Participants were not informed of their allocation. The operating surgeon was necessarily aware of allocation.
INTERVENTION
All procedures were performed by a single surgeon under spinal or general anaesthesia, using a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation. Energy was delivered by a Ceralas dual-wavelength diode laser system (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, through a bare-tip fibre in continuous-wave mode at a total power of 140 W. Laser wavelength, fibre type, emission mode and power setting were identical in both arms.
Conventional arm: vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, including tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created.
Ejaculation-preserving arm: no vaporization was performed within 10 mm distal to the bladder neck, and no vaporization was performed within 10 mm proximal to the verumontanum. Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm. Adherence to both margins was recorded prospectively in every case.
ASSESSMENTS
Participants were assessed at baseline and at day 7 to 14, 1 month, 3 months, 6 months and 12 months. Symptoms were quantified with the International Prostate Symptom Score and its quality-of-life item, and erectile function with the five-item International Index of Erectile Function. Uroflowmetry was accepted only with a voided volume of at least 150 mL. Post-void residual volume and prostate volume were measured by transabdominal ultrasound. Ejaculatory status was recorded as a binary patient-reported outcome: presence or absence of any antegrade ejaculate during sexual activity since the preceding visit. Complications were graded using the Clavien-Dindo classification.
ANALYSIS
Continuous variables were compared between arms with the Mann-Whitney U test and within arms against baseline with the Wilcoxon signed-rank test. Proportions were compared with the two-sided Fisher exact test, with risk differences reported using Newcombe hybrid-score 95 percent confidence intervals. No imputation was performed. Analysis was restricted to participants with complete records at every scheduled visit.
NOTE ON REGISTRATION
This trial was registered retrospectively. The protocol, including the primary endpoint, the secondary endpoints and the two 10 mm technical margins, was submitted to and registered by the Scientific Committee of the Department of Clinical Sciences, College of Medicine, University of Sulaimani (number 28, 25 February 2025) and approved by the Ethics Committee of the same institution (number 62, 2 March 2025). Public registry registration was not undertaken before enrolment because the requirement was not appreciated at the time. No outcome measures, eligibility criteria or analysis definitions were altered after the study began.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Kurdistan
-
Sulaymaniyah, Kurdistan, Irak, 46001
- Royal Hospital, Department of Urology
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Male, aged 50 years or older
- Lower urinary tract symptoms attributable to benign prostatic obstruction
- International Prostate Symptom Score of 16 or more
- Maximum urinary flow rate below 15 mL/s on a uroflowmetry study with a voided volume of at least 150 mL
- Prostate volume between 30 and 150 cc on transabdominal ultrasound
- Indication for surgery after failure of or intolerance to medical therapy
- Preserved antegrade ejaculation at baseline
- Currently sexually active
- Willing and able to attend all scheduled follow-up visits
- Written informed consent, including specific consent to discussion and recording of ejaculatory function
Exclusion Criteria:
- Suspected or confirmed prostate cancer
- Prostate-specific antigen above the age-specific reference range without a benign explanation
- Neurogenic bladder
- Urethral stricture
- Bladder stones
- Previous prostatic or urethral surgery
- Absent antegrade ejaculation at baseline
- Erectile dysfunction sufficient to preclude sexual activity
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: conventional tuvp
Conventional dual-wavelength diode laser vaporization of the prostate.
Vaporization proceeded from the bladder neck to the verumontanum in the standard fashion, with removal of obstructing adenoma including the tissue at the bladder neck and immediately proximal to the verumontanum, until a wide channel was created
|
Transurethral vaporization of the prostate using a Ceralas dual-wavelength diode laser (biolitec biomedical technology GmbH, Jena, Germany) emitting simultaneously at 980 nm and 1470 nm, bare-tip fibre, continuous wave, total power 140 W, delivered through a 22 Fr continuous-flow laser cystoscope sheath with normal saline irrigation, under spinal or general anaesthesia.
Adenoma was vaporized from the bladder neck to the verumontanum without preservation margins.
|
|
Experimenteel: Ejaculation-Preserving TUVP (EP-TUVP)
Ejaculation-preserving dual-wavelength diode laser vaporization of the prostate.
No vaporization was performed within 10 mm distal to the bladder neck, preserving the circular muscle fibres of the internal sphincter, and no vaporization was performed within 10 mm proximal to the verumontanum, preserving the paracollicular and supracollicular tissue.
Between these two margins, the lateral lobes, median lobe and anterior tissue were vaporized to the same endpoint as in the conventional arm.
Laser settings were identical to the comparator arm.
|
Identical equipment, laser settings and anaesthesia to the comparator intervention, with two preservation margins: no vaporization within 10 mm distal to the bladder neck and none within 10 mm proximal to the verumontanum.
Adequacy of the mid-prostatic channel was confirmed endoscopically at the end of the procedure.
Adherence to both margins was recorded prospectively for every case.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Preservation of antegrade ejaculation
Tijdsspanne: 3 months after surgery
|
Proportion of participants reporting the presence of any antegrade ejaculate during sexual activity since the preceding visit.
Recorded as a binary patient-reported outcome (present or absent).
All participants had antegrade ejaculation at baseline as an eligibility requirement.
|
3 months after surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Durability of integrate ejaculation preservation
Tijdsspanne: 6 and 12 months after surgery
|
Proportion of participants reporting presence of any antegrade ejaculate, assessed as for the primary outcome, to test whether any benefit is sustained over time.
|
6 and 12 months after surgery
|
|
Change in international prostate symptom score IPSS
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
IPSS total score, range 0 to 35, where higher scores indicate more severe lower urinary tract symptoms.
Change from baseline is reported.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in IPSS quality of life score
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
Single-item IPSS quality-of-life question, range 0 to 6, where higher scores indicate worse bother from urinary symptoms.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in maximum urinary flow rate (Qmax)
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
Maximum flow rate in mL/s measured by uroflowmetry, accepted only when voided volume was at least 150 mL.
Higher values indicate better flow.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in post-void residual urine volume
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
Post-void residual volume in mL measured by transabdominal ultrasound.
Lower values indicate more complete bladder emptying.
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in prostate volume
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
prostate volume in cc measured by transabdominal ultrasound, using the prolate, elipsoid formula with percentage reduction from baseline calculated
|
Baseline, 3, 6, and 12 months after surgery
|
|
Change in erectile function (IIEF-5)
Tijdsspanne: Baseline, 3, 6, and 12 months after surgery
|
Five-item International Index of Erectile Function, range 5 to 25, where higher scores indicate better erectile function.
Assessed as a control variable to distinguish ejaculatory from erectile outcomes.
Face like, three, six, and 12 months after
|
Baseline, 3, 6, and 12 months after surgery
|
|
Complications graded by Clavien-Dindo classification
Tijdsspanne: From surgery to 12 months after surgery
|
Clavien-Dindo grade recorded per participant, from grade I (any deviation from normal course) to grade V (death), including in-hospital and all follow-up intervals.
|
From surgery to 12 months after surgery
|
|
Patient global satisfaction
Tijdsspanne: 3, 6, and 12 months after surgery
|
Patient-reported global satisfaction with the outcome of surgery on a 5-point scale, where 1 indicates very dissatisfied and 5 indicates very satisfied.
|
3, 6, and 12 months after surgery
|
|
Trifecta outcome
Tijdsspanne: 12 months after surgery
|
Composite endpoint requiring all three of: IPSS below 8, complete pad independence, and preserved antegrade ejaculation.
|
12 months after surgery
|
|
Operative time, catheterization time and hospital stay
Tijdsspanne: Day of surgery to hospital discharge, up to seven days
|
Operative time in minutes measured from insertion to withdrawal of the cystoscope, duration of postoperative catheterisation in hours, and length of hospital stay in hours.
|
Day of surgery to hospital discharge, up to seven days
|
|
Early post operative dysuria
Tijdsspanne: Day 7 to 14 and 1month after surgery
|
Dysuria severity on a visual analogue scale from 0 to 10, where higher scores indicate more severe dysuria, together with the duration of dysuria in days.
|
Day 7 to 14 and 1month after surgery
|
|
Re-treatment for benign prostatic obstruction
Tijdsspanne: Up to 12 months after surgery
|
Proportion of participants requiring any further surgical intervention for benign prostatic obstruction.
|
Up to 12 months after surgery
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Emam A, Nabil Habib K, Teama K, Samir Y, Sadeq MM, Gamal MA. "Laser vaporization of the prostate: A comparative study between ejaculatory preserving and non-ejaculatory preserving technique". Arab J Urol. 2024 Jul 4;23(1):8-15. doi: 10.1080/20905998.2024.2375677. eCollection 2025.
- Ramez M, Abolazm AE, El-Nahas AR. Ejaculatory-sparing transurethral prostatectomy: a meta-analysis of randomized controlled trials. Sex Med Rev. 2024 Sep 25;12(4):754-760. doi: 10.1093/sxmrev/qeae054.
- Abolazm AE, El-Hefnawy AS, Laymon M, Shehab-El-Din AB, Elshal AM. Ejaculatory Hood Sparing versus Standard Laser Photoselective Vaporization of the Prostate: Sexual and Urodynamic Assessment through a Double Blinded, Randomized Trial. J Urol. 2020 Apr;203(4):792-801. doi: 10.1097/JU.0000000000000685. Epub 2019 Nov 25.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Ejaculatie disfunctie
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Ziekten van de urineblaas
- Seksuele disfunctie, fysiologisch
- Urethrale ziekten
- Urethrale obstructie
- Prostaathyperplasie
- Obstructie van de urineblaashals
- Retrograde Ejaculation
Andere studie-ID-nummers
- UOS-COM-62-2024
- UOS-COM-ETHICS-62 (Andere identificatie: Ethics Committee, College of Medicine, University of Sulaimani)
- UOS-CSD-REG-28 (Andere identificatie: Clinical Sciences Department Scientific Committee, University of Sulaimani)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .